Termination of experimental galactosemia in rats, and progression of retinal metabolic abnormalities

Investigative Ophthalmology and Visual Science

Volumn 43, Issue 10, 2002, Pages 3287-3291

  Kowluru, Renu A ^a   Koppolu, Prashant ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ANTIOXIDANT; GLUTATHIONE; LIPID PEROXIDE; NITRIC OXIDE; PEROXYNITRITE; PROTEIN KINASE C;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; DISEASE COURSE; ENZYME ACTIVATION; ENZYME ACTIVITY; GALACTOSEMIA; HYPERGLYCEMIA; MALE; METABOLIC DISORDER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RETINA; RETINOPATHY;

ANIMALS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; GALACTOSE; GALACTOSEMIAS; GLUTATHIONE; HEXOSES; LIPID PEROXIDES; MALE; METABOLIC DISEASES; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; PROTEIN KINASE C; RATS; RATS, SPRAGUE-DAWLEY; RETINA; RETINAL DISEASES; TYROSINE;

EID: 0036784939     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
2. Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes. 1987;36:808-812.
3. Armstrong D, Abdella N, Salman A, Miller N, Rahman EA, Bojancyzk M. Relationship of lipid peroxides to diabetic complications. J Diabetes Complications. 1992;6:116-122.
4. Kowluru RA, Kern TS, Engerman RL. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. IV: antioxidant defense system. Free Radic Biol Med. 1996;22:587-592.
5. Stitt AW, Li M, Gardiner TA, Bucala R, Archer DB, Vlassara H. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol. 1997;150:523-531.
6. Kador PF, Akagi Y, Takahashi Y, Ikebe H, Wyman M, Kinoshita J H. Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol. 1990;108:1301-1309.
7. Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, King GL. Characterization of the mechanism for the chronic activation of DAG-PKC pathway in diabetes and hypergalactosemia. Diabetes. 1994;43:1122-1129.
8. Kowluru RA, Jirousek MR, Stramm LE, Farid NA, Engerman RL, Kern TS. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. V. Relationship between protein kinase C and ATPases. Diabetes. 1998;47:464-469.
9. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787-790.
10. Kowluru RA. Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are inter-related. Acta Diabetol. 2001;38:179-185.
11. Engerman RL, Kern TS. Hyperglycemia as a cause of diabetic retinopathy. Metabolism. 1986;35(suppl 1):20-23.
12. Kowluru RA, Kern TS, Engerman RL, Armstrong D. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. III: effects of antioxidants. Diabetes. 1996;45:1233-1237.
13. Kowluru RA, Tang J, Kern TS. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII: effect of long-term administration of antioxidants on the development of retinopathy. Diabetes. 2001;50:1938-1942.
14. UKPDS [United Kingdom Prospective Diabetes Study]. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837-853.
15. Engerman RL, Kern TS. Retinopathy in galactose-fed dogs continues to progress after cessation of galactosemia. Arch Ophthalmol. 1995;113:355-358.
16. Robison WGJ, Laver NM, Jacot JL, Chandler ML, York BM, Glover JP. Efficacy of treatment after measurable diabetic like retinopathy in galactose-fed rats. Invest Ophthalmol Vis Sci. 1997;38:1066-1073.
17. Robison WG, Jacot JL, Glover JP, Basso MD, Hohman TC. Diabetic-like retinopathy: early and late intervention therapies in galactose-fed rats. Invest Ophthalmol Vis Sci. 1998;39:1933-1941.
18. Jain SK, Abreo K, Duett J, Sella M. Lipofuscin products, lipid peroxides and aluminum accumulation in red blood cells of hemodialyzed patients. Am J Nephrol. 1995;15:306-311.
19. Kowluru RA, Engerman RL, Kern TS. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. VIII: prevention by aminoguanidine. Curr Eye Res. 2000;21:814-819.
20. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKCβ inhibitor. Science. 1996;272:728-731.
21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein. Anal Biochem. 1974;72:248- 258.
22. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991;40:405-412.
23. Armstrong D, Al-Awadi F. Lipid peroxidation and retinopathy in streptozotocin-induced diabetes. Free Radic Biol Med. 1991;11: 433-436.
24. Wohaieb SA, Godin DV. Alterations in free radical tissue-defense mechanisms in streptozotocin-induced diabetes. Diabetes. 1987; 36:1014-1018.
25. Obrosova IG, Fathallah L, Greene DA. Early changes in lipid peroxidation and antioxidative defense in diabetic rat retina: effect of DL-alpha-lipoic acid. Eur J Pharmacol. 2000;398:139-146.
26. Heath H, Rutter AC, Beck TC. Changes in the ascorbic acid and glutathione content of the retinae and adrenals from alloxan- diabetic rats. Vision Res. 1962;2:431-437.
27. Li W, Yanoff M, Jian B, He Z. Altered mRNA levels of antioxidant enzymes in pre-apoptotic pericytes from human diabetic retinas. Cell Mol Biol. 1999;45:59-66.
28. Robison WG, Jacot JL, Katz ML, Glover JP. Retinal vascular changes induced by the oxidative stress of alpha-tocopherol deficiency contrasted with diabetic microangiopathy. J Ocul Pharmacol Ther. 2000;16:109-120.
29. Miralles C, Busquets X, Santos C, et al. Regulation of iNOS expression and glutathione levels in rat liver by oxygen tension. FEBS Lett. 2000;476:253-257.
30. Tilton RG, Chang K, Hasan KS, et al. Prevention of diabetic vascular dysfunction by guanidines: inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes. 1993; 42:221-232.
31. Szabo C. DNA strand breakage and activation of poly-ADP ribotransferase: a cytotoxic pathway triggered by peroxynitrite. Free Radic Biol Med. 1996;21:855-869.
32. Halliwell B. What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo. FEBS Lett. 1997;411: 157-160.
33. Palumbo EJ, Sweatt JD, Chen S-J, Klann E. Oxidation-induced persistent activation of protein kinase C in hippocampal homogenates. Biochem Biophys Res Commun. 1992;187:1438-1445.
34. Nagpala PG, Malik AB, Vuong PT, Lum H. Protein kinase C beta-1 overexpression augments phorbol ester-induced increase in endothelial permeability. J Cell Physiol. 1996;166:249-255.
35. Shiba T, Inoguchi T, Sportsman JR, Heath WF, Bursell S, King GL. Correlation of diacylglycerol and protein kinase C in rat retina to retinal circulation. Am J Physiol. 1993;265:E783-E793.
36. Drewes LR, Broderius MA, Gerhart DZ. Phorbol ester stimulates hexose uptake by brain microvessel endothelial cells. Brain Res Bull. 1988;21:771-776.
37. Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int. 2000;77:S113-S119.
38. Mohr S, Xi X, Tang J, Kern TS. Caspase activation in retinas of diabetic and galactosemic mice and diabetic patients. Diabetes. 2002;51:1172-1179.
39. Kern TS, Tang J, Mizutani M, Kowluru R, Nagraj R, Lorenzi M. Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. Invest Ophthalmol Vis Sci. 2000;41:3972-3978.
40. Kern TS, Engerman RL. Galactose-induced retinal microangiopathy in rats. Invest Ophthalmol Vis Sci. 1995;36:490-496.
41. Frank RN, Amin R, Kennedy A, Hohman TC. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term diabetes. Arch Ophthalmol. 1997;115:1036-1045.
42. Hammes H-P, Klinzing I, Wiegand S, Bretzel RG, Cohen AM, Federlin K. Islet transplantation inhibits diabetic retinopathy in the sucrose-fed diabetic Cohen diabetic rat. Invest Ophthalmol Vis Sci. 1993;34:2092-2096.
43. Stewart MA, Kurien MW, Sherman WR, Cotlier EV. Inositol changes in nerve and lens of galactose fed rats. J Neurochem. 1968;15:941-946.